Division of Allergy & Immunology

Clinical Trials

The Division of Allergy/Immunology is currently recruiting patients for the following trials:

  1. EXACT: A Prospective, Randomized, Double-Blind Study of the Efficacy of Xolair® in Atopic Asthmatics with Good Lung Capacity who Remain Difficult to Treat
  2. MOLLY: A Phase II, Randomized, Double-Blind, Placebo-Lebrikizumab (MILR1444A) in Adult Patients with Asthma who are not Taking Inhaled Corticosteroids
  3. HZA106837: A Long-Term, Randomized, souble-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once Daily in Subjects with Asthma  
  4. Efficacy of early introduction of allergy immunotherapy in young children to reduce long-term asthma morbidity (AIR study) NCT01028560
  5. Diagnosis of Aspirin Hypersensitivity by Measuring Arachidonic Acid Metabolites after Low Dose Aspirin Challenge


Currently we are recruiting adult patients with the following conditions:

  • Asthma, who use frequent albuterol despite being on inhaled steroids
  • Asthma, who do not take any controller medications
  • Asthma, who take medications, but do not need albuterol often
  • Asthma and aspirin allergy

We are also recruiting children 18 months to 3 years of age with at least 2 episodes of wheezing prior to the study enrollment.

Past Clinical Trials 

  1. TENOR Genetech, INC
  3. STEAM AstraZeneca--A twelve-week, randomized, double-blind, double-dummy, placebo and active controlled study of SYMBICORT pMDI administered once daily in adults adolesents with asthma--2003-2005
  4. PEGASUS-002 Pfizer
  5. ATLANTIS AstraZeneca---A two-stage randomized, parallel group, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT pMDI administered either as fixed or as an adjustable regimen versus a fixed regimen of Advair in subjects 12 years of age and older with asthma---2004-2005
  6. EXELS Genetech, INC---An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-term in Patients with Moderate to Severe Asthma---2005-cont
  7. SFA100062 GSK---A Randomized.Parallel-Group, Double-Blind, ComparativeTrial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Persistent Asthma, Who Have Either a B16-Arg/Arg, a B16-Gly/Gly, or a B16-Arg/Gly Genotype and are Treated with Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg or Salmeterol DISKUS Product 100/50 mcg or Salmeterol DISKUS 50 mcg BID---2005-2006
  8. Xolair immunotherapy (PI) Novartis---A 26-week, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the effect of Xolair (omalizumab) on improving the tolerability of specific immunotherapy in patients with persistent allergic asthma--- 2006-2007
  9. EXTRA (PI) Genetech, INC---A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma Who Are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists--2006-2007
  10. A-a study AstraZeneca---A 52-week, randomized, double-blind, parallel-group, multi-centre, Phase IIIB study comparing the long term safety of SYMBICORT pMDI 160/4.5 ug X 2 actuations twice daily to budesonide HFA pMDI 160 ug x 2 actuations twice daily in adult and adolescent (greater than or equal to 12 years) African American subjects with asthma--2007
  11. Back to scholl study Merck A Multicenter, Randomized,Double-blind, Placebo-Controlled Parallel Group 8-Week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School Year in Pediatric Patients with Chronic Asthma—2006
  12. Asthma anti IL-13 Wyeth--A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 3 Dose Levels of IMA-638 in Subjects with Persistent Asthma--2007
Click here to log in